Led by Annette Byrne, Associate Professor, Royal College of Surgeons in Ireland (RSCI) Department of Physiology and Medical Physics, in partnership with leading clinical investigators and researchers spanning eight European countries, the Horizon 2020-supported COLOSSUS–Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems based patient stratification solutions, launched in early 2018 to more precisely define molecular subclasses of colorectal cancer (CRC).
By studying patient samples and applying cutting-edge, multi-omic modelling approaches, this Consortium is set to drive important progress towards developing, matching and measuring novel therapies according to the specificities of each identified molecular subtype.
Powered by 14 partners, including VHIO, with expertise in cancer immunology, systems biology, computational modelling, bioinformatics, omics analysis, clinical oncology/pathology, preclinical research, medical imaging, clinical trials, health economics and patient management, this five-year research program focuses on microsatellite stable RAS mutant (MSS RAS mt) disease – a genetically identified type of CRC with very few therapeutic options available once patients develop resistance to existing chemotherapies.
The COLOSSUS team strives to both expand and refine the classification of this particular subset of colorectal cancer. Reflective of its promise to deliver multidisciplinary team science of excellence, the COLOSSUS proposal ranked first among the other 200 European projects that were submitted to the Horizon 2020 Personalized Medicine Call for New Concepts in Patient Stratification.
To discover more, we invite you to watch the COLOSSUS Explainer video here:
https://www.youtube.com/watch?v=-Zxym7__7yA&feature=youtu.be
To access the project’s website visit: www.colossusproject.eu
For more about VHIO’s participation in COLOSSUS please contact Amanda Wren, Director of Communications, Vall d’Hebron Institute of Oncology (VHIO), Email: awren@vhio.net.
